FDA approves three new drugs for Type 2 diabetes

Takeda's Nesina, Kazano, Oseni receive approval

SILVER SPRING, Md. — The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said Friday.

The FDA announced the approval of Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone) tablets.

Alogliptin is a new active ingredient, while metformin and pioglitazone are drugs already on the market.

"Controlling blood sugar levels is very important in the overall treatment and care of diabetes," FDA Division of Metabolism and Endocrinology Products director Mary Parks said. "Alogliptin helps stimulate the release of insulin after a meal, which leads to better blood sugar control."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.